NF-κB transcription factor in cancer
DOI:
https://doi.org/10.24265/horizmed.2023.v23n1.12Keywords:
NF-kappa B, neoplasms, neoplasm metastasisAbstract
The nuclear factor kappa B (NF-κB) family of transcription factors, which regulates a large range of genes in various immunological and inflammatory response pathways, is of utmost importance. This family consists of five structurally similar members that can activate target genes by attaching to particular regions of deoxyribonucleic acid (DNA). A class of inhibitory proteins usually keep NF-κB proteins in the cytoplasm; however, different oncogenic signaling pathways
can activate them and cause malignant phenotypes in the appropriate cells. The main goal of this review article is to understand the regulatory mechanisms of NF-κB transcription factor, its pathogenesis and its potential cancer therapies. From the year 2000 to December 2022, several databases, including PubMed, Scopus and SciELO, were consulted. Finally, the review was developed by searching bibliographic references looking for the keywords related to NF-κB and cancer.
The NF-κB transcription factor plays a key role in numerous cell signaling pathways, is involved in a number of biological functions, and its mutations have been linked to cancer and immunological disorders, among other pathologies. Since NF-κB is expressed in all cell types and tissues, many oncogenic mutations can activate NF-κB in tumor cells, opening up new research possibilities for the treatment of cancer. The canonical pathway and the alternative (non-canonical)
pathway are two distinct NF-κB signaling pathways with various activation methods. NF-κB is involved in a variety of oncogenic pathways, including chronic inflammation, proliferation, apoptosis, angiogenesis, effect on cancer stem cells, metastasis, metabolic control and other related mechanisms. In conclusion, there are still many unanswered questions regarding the mechanisms and functions of NF-κB in the cellular context. A complete blockade of NF-κB does not appear
to be a feasible strategy for the treatment of cancer at this time due to the variety of significant physiological actions that are altered by its blockade. Future research on NF-κB should focus on preventing cancer promotion while preserving the body’s natural physiological processes.
Downloads
References
Mitsis T, Efthimiadou A, Bacopoulou F, Vlachakis D, Chrousos GP, Eliopoulos E. Transcription factors and evolution: An integral part of gene expression (Review). World Acad Sci J. 2020;2(1):3-8.
Sen R, Baltimore D. Multiple nuclear factors interact with the immunoglobulin enhancer sequences. Cell. 1986;46(5):705-16.
Perkins ND. The Rel/NF-kappa B family: friend and foe. Trends Biochem Sci. 2000;25(9):434-40.
Liu T, Zhang L, Joo D, Sun SC. NF-?B signaling in inflammation. Signal Transduct Target Ther. 2017;2:(e17023).
Zhang T, Ma C, Zhang Z, Zhang H, Hu H. NF-?B signaling in inflammation and cancer. MedComm (2020). 2021;2(4):618-53.
Huxford T, Ghosh G. A structural guide to proteins of the NF-kappaB signaling module. Cold Spring Harb Perspect Biol. 2009;1(3):a000075.
Hayden MS, Ghosh S. Shared principles in NF-kappaB signaling. Cell. 2008;132(3):344-62.
Karin M, Greten FR. NF-kappaB: linking inflammation and immunity to cancer development and progression. Nat Rev Immunol. 2005;5(10):749-59.
Yu H, Lin L, Zhang Z Zhang H, Hu H. Targeting NF-?B pathway for the therapy of diseases: mechanism and clinical study. Sig Transduct Target Ther. 2020;5(1):1-23.
Sun SC. Non-canonical NF-?B signaling pathway. Cell Res. 2011;21(1):71-85.
Sun SC. The non-canonical NF-?B pathway in immunity and inflammation. Nat Rev Immunol. 2017;17(9):545-58.
Israel A. The IKK complex, a central regulator of NF-kappaB activation. Cold Spring Harb Perspect Biol. 2010;2(3):a000158.
Sun SC, Ley SC. New insights into NF-kappaB regulation and function. Trends Immunol. 2008;29(10):469-78.
Karin M. Nuclear factor-KB in cancer development and progression. Nature. 2006;441(7092):431-6.
Cildir G, Low KC, Tergaonkar V. Noncanonical NF-?B Signaling in Health and Disease. Trends Mol Med. 2016;22(5):414-29.
Yang XD, Sun SC. Targeting signaling factors for degradation, an emerging mechanism for TRAF functions. Immunol Rev. 2015, 266(1):56-71.
Xiao G, Harhaj EW, Sun SC. NF-kappaB-inducing kinase regulates the processing of NF-kappaB2 p100. Mol Cell. 2001;7(2):401-9.
Betts JC, Nabel GJ. Differential regulation of NF-kappaB2(p100) processing and control by amino-terminal sequences. Mol Cell Biol. 1996;16(11):6363-71.
Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA, Kinzler KW. Cancer genome landscapes. Science. 2013;339(6127):1546-58.
Lawrence MS, Stojanov P, Mermel CH, Robinson JT, Garraway LA, Golub TR, et al. Discovery and saturation analysis of cancer genes across 21 tumour types. Nature. 2014;505(7484):495-501.
Mendiratta G, Ke E, Aziz M, Liarakos D, Tong M, Stites EC. Cancer gene mutation frequencies for the U.S. population. Nat Commun. 2021;12(1):5961.
Weniger MA, Kuppers R. Molecular biology of Hodgkin lymphoma. Leukemia. 2021;35(4):968-81.
Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646-74.
Terzic J, Grivennikov S, Karin E, Karin M. Inflammation and colon cancer. Gastroenterology. 2010;138(6):2101-14.e5.
Guttridge DC, Albanese C, Reuther JY, Pestell RG, Baldwin AS. NFkappaB controls cell growth and differentiation through transcriptional regulation of cyclin D1. Mol Cell Biol. 1999;19(8):5785-99.
Nam SY, Ko YS, Jung J, Yoon J, Kim YH, Choi YJ, et al. A hypoxiadependent upregulation of hypoxia-inducible factor-1 by nuclear factor-?B promotes gastric tumour growth and angiogenesis. Br J Cancer. 2011;104(1):166-74.
Barkett M, Gilmore TD. Control of apoptosis by Rel/NF-kappaB transcription factors. Oncogene. 1999;18(49):6910-24.
Gilmore TD. NF-?B and Human Cancer: What have we learned over the past 35 years? Biomedicines. 2021;9(8):889.
Basseres DS, Ebbs A, Levantini E, Baldwin AS. Requirement of the NF-kappaB subunit p65/RelA for K-Ras-induced lung tumorigenesis. Cancer Res. 2010;70(9):3537-46.
Forsythe JA, Jiang BH, Iyer NV, Agani F, Leung SW, Koos RD, et al. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol. 1996;16(9):4604-13.
Huang S, Pettaway CA, Uehara H, Bucana CD, Fidler IJ. Blockade of NF-kappaB activity in human prostate cancer cells is associated with suppression of angiogenesis, invasion, and metastasis. Oncogene. 2001;20(31):4188-97.
Iwasaki K, Yabushita H, Ueno T, Wakatsuki A. Role of hypoxiainducible factor-1a, carbonic anhydrase-IX, glucose transporter-1 and vascular endothelial growth factor associated with lymph node metastasis and recurrence in patients with locally advanced cervical cancer. Oncol Lett. 2015;10(4):1970-78.
Chen W, Dong J, Haiech J, Kilhoffer MC, Zeniou M. Cancer Stem Cell Quiescence and Plasticity as Major Challenges in Cancer Therapy. Stem Cells Int. 2016;2016:1740936.
Vazquez-Santillan K, Melendez-Zajgla J, Jimenez-Hernandez L, Martinez-Ruiz G, Maldonado V. NF-?B signaling in cancer stem cells: a promising therapeutic target? Cell Oncol (Dordr). 2015;38(5):327-39.
Rinkenbaugh AL, Baldwin AS. The NF-?B pathway and cancer stem cells. Cells. 2016;5(2):16.
Kawauchi K, Araki K, Tobiume K, Tanaka N. p53 regulates glucose metabolism through an IKK-NF-kappaB pathway and inhibits cell transformation. Nat Cell Biol. 2008;10(5):611-8.
Mauro C, Leow SC,Anso E, Rocha S, ThotakuraAK, Tornatore L, et al. NF-?B controls energy homeostasis and metabolic adaptation by upregulating mitochondrial respiration. Nat Cell Biol. 2011;13(10):1272-9.
Ding D, Xi P, Zhou J, Wang M, Cong YS. Human telomerase reverse transcriptase regulates MMP expression independently of telomerase activity via NF-?B-dependent transcription. FASEB J. 2013;27(11):4375-83.
Scheel C, Weinberg RA. Cancer stem cells and epithelialmesenchymal transition: concepts and molecular links. Semin Cancer Biol. 2012;22(5-6):396-403.
Drabsch Y, ten Dijke P. TGF-ï¿1/2 signalling and its role in cancer progression and metastasis. Cancer Metastasis Rev. 2012;31(34):553-68.
Collins T, Read MA, Neish AS, Whitley MZ, Thanos D, Maniatis T. Transcriptional regulation of endothelial cell adhesion molecules: NFkappa B and cytokine-inducible enhancers. FASEB J. 1995;9(10):899-909.
Nguyen DX, Bos PD, Massague J. Metastasis: from dissemination to organ-specific colonization. Nat Rev Cancer. 2009;9(4):274-84.
Matsumoto Y, Marusawa H, Kinoshita K, Endo Y, Kou T, Morisawa T, et al. Helicobacter pylori infection triggers aberrant expression of activation-induced cytidine deaminase in gastric epithelium. Nat Med. 2007;13(4):470-6.
Colotta F, Allavena P, Sica A, Garlanda C, Mantovani A. Cancerrelated inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis. 2009;30(7):1073-81.
Lin Y, Bai L, Chen W, Xu S. The NF-kappaB activation pathways, emerging molecular targets for cancer prevention and therapy. Expert Opin Ther Targets. 2010;14(1):45-55.
Gilmore TD, Garbati MR. Inhibition of NF-?B signaling as a strategy in disease therapy. Curr Top Microbiol Immunol. 2011;349:245-63.
Vrabel D, Pour L, Sevcikova S. The impact of NF-?B signaling on pathogenesis and current treatment strategies in multiple myeloma. Blood Rev. 2019;34:56-66.
Sherman DJ, Li J. Proteasome Inhibitors: Harnessing Proteostasis to Combat Disease. Molecules. 2020;25(3):671.
Hanley DA, Adachi JD, Bell A, Brown V. Denosumab: mechanism of action and clinical outcomes. Int J Clin Pract. 2012;66(12):1139-46.
Gao S, Wang S, Song Y. Novel immunomodulatory drugs and neosubstrates. Biomark Res. 2020;8(1):2.
Brullo C, Villa C, Tasso B, Russo E, Spallarossa A. Btk Inhibitors: A Medicinal Chemistry and Drug Delivery Perspective. Int J Mol Sci. 2021;22(14):7641.
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Horizonte Médico (Lima)
This work is licensed under a Creative Commons Attribution 4.0 International License.
Horizonte Médico (Lima) (Horiz. Med.) journal’s research outputs are published free of charge and are freely available to download under the open access model, aimed at disseminating works and experiences developed in biomedical and public health areas, both nationally and internationally, and promoting research in the different fields of human medicine. All manuscripts accepted and published in the journal are distributed free of charge under the terms of a Creative Commons license – Attribution 4.0 International (CC BY 4.0).
